AzTrials
AzTrials

Non-Small Cell Lung CancerPhase 2ORCHARDNCT03944772

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

A Phase 2 study testing Osimertinib, Savolitinib and Gefitinib in people with Non-Small Cell Lung Cancer, run by AstraZeneca at 47 sites in 9 countries.

Active, not recruiting

Under way, not looking for participants. Everyone needed has enrolled. The study is still running.

Official record
Search all trials

Trial summary

Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments. Read more about this study

Who is it for?
Ages 18 to 130 years
Conditions the study is for
Non-Small Cell Lung Cancer
What is being tested?
Osimertinib, Savolitinib and Gefitinib
Could I receive a placebo?
No, everyone receives an active treatment
How many people
247 participants
Where
47 sitesin 9 countries
Study dates
25 Jun 2019to 6 May 2025
Phase
Phase 2
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 130 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Inclusion criteria applicable to all study treatment modules (Group A \& B)

  1. NSCLC with the following features:
  2. Locally advanced or metastatic disease (ie, advanced NSCLC) not amenable to curative surgery or radiotherapy at study entry.
  3. Histologically or cytologically confirmed adenocarcinoma of the lung (patients with mixed histology are eligible if adenocarcinoma is the predominant histology) harboring EGFR mutation(s) known to be associated with EGFR TKI sensitivity at diagnosis. Any histologically identifiable component of neuroendocrine transformation to SCLC or large cell NEC is required for treatment under Module 7.
  4. Received only one line of therapy, with single-agent osimertinib, for advanced NSCLC, with clinical benefit as judged by investigator discretion. (Note: a 'line' of therapy is defined as a daily anti-cancer treatment administered for >14 days, or a single infusion of an intravenous anti-cancer treatment. For instance, patients who have had <14 days of a first- or second- generation TKI prior to osimertinib, and stopped due to adverse events, would be eligible to enter this study, see also exclusion criteria 5). Patients previously treated adjuvantly or neo-adjuvantly are eligible per exclusion criterion 5.
  5. Evidence of radiological disease progression on first-line monotherapy with osimertinib 80 mg po QD.
  6. Suitable for a mandatory biopsy defined as having an accessible tumor; by whichever modality the site uses and, ideally, confirmed by the person who will perform the procedure; and a stable clinical condition that will allow the patient to tolerate the procedure. The biopsy should be performed within 60 days of the planned first dose of study treatment.
  7. Patients must have measurable disease per RECIST 1.1, as defined by at least 1 lesion that can be accurately measured at baseline as ≥ 10 mm at the longest diameter (except lymph nodes which must have a short axis ≥ 15 mm) with computed tomography (CT) or magnetic resonance imaging (MRI), which is suitable for accurate repeated measurements. Previously irradiated lesions or a lesion in the field of radiation should not be used as measurable disease unless the lesion(s) has/have demonstrated unequivocal disease progression by RECIST 1.1. Target lesions should not be used for the baseline tumour biopsy, unless there are no other lesions suitable for biopsy and they fulfil requirements.
  8. Adequate coagulation parameters, defined as:

International Normalisation Ratio (INR) < 1.5 × upper limit of normal (ULN) and activated partial thromboplastin time < 1.5 × ULN unless patients are receiving therapeutic anti-coagulation which affects these parameters.

-------------------------------------------------------------------------------------------

Exclusion Criteria applicable to all study treatment modules (Groups A/B):

  1. Patients whose disease has progressed within the first 3 months of osimertinib treatment (refractory to osimertinib treatment).
  2. Patients must not have experienced a toxicity(-ies) that led to permanent discontinuation or dose reduction of prior osimertinib. (a) Patients who had dose reductions in the past, but were receiving a full dose of osimertinib at the time of pre-screening should be discussed with the Study Physician.
  3. Any unresolved toxicities from prior osimertinib treatment greater than CTCAE Grade 1 at the time of starting study treatment.
  4. Patients should not have discontinued osimertinib >60 days prior to the first dose of study treatment.
  5. Inadequate bone marrow reserve or organ function as demonstrated by any of the following laboratory values:
  6. Absolute neutrophil count < 1.5 × 109/L.
  7. Platelet count < 100 × 109/L.
  8. Haemoglobin < 9 g/dL.
  9. Alanine transaminase (ALT) > 2.5 × ULN.
  10. Aspartate aminotransferase (AST) > 2.5 × ULN.
  11. Total bilirubin (TBL) > 1.5 × ULN, or > 3 × ULN in the presence of documented Gilbert's Syndrome (unconjugated hyperbilirubinaemia).
  12. Creatinine clearance (CrCl) < 50 mL/min, calculated using Cockcroft-Gault equation (Cockcroft and Gault 1976) or 24-hour urine collection. For medical conditions where the Cockcroft-Gault equation is inappropriate or 24-hour urine collection is unfeasible, CrCl may be calculated differently following written approval from the Study Physician.

Trial locations and contacts

47 sites in 9 countries.

47 sites in 9 countries

United States16 sites

  • Research Site

    Baltimore, Maryland, 21224

  • Research Site

    Boston, Massachusetts, 02114

  • Research Site

    Boston, Massachusetts, 02215

  • Research Site

    Chicago, Illinois, 60612

  • Research Site

    Duarte, California, 91010

  • Research Site

    Grand Rapids, Michigan, 49503

  • Research Site

    Houston, Texas, 77030

  • Research Site

    Los Angeles, California, 90048

  • Research Site

    New Haven, Connecticut, 06510

  • Research Site

    New York, New York, 10017

  • Research Site

    New York, New York, 10032

  • Research Site

    Pittsburgh, Pennsylvania, 15232

  • Research Site

    Portland, Oregon, 97239

  • Research Site

    Sacramento, California, 95817

  • Research Site

    Santa Monica, California, 90404

  • Research Site

    Seattle, Washington, 98109

Other trials in United States

Japan6 sites

  • Research Site

    Chūōku, 104-0045

  • Research Site

    Fukuoka, 812-8582

  • Research Site

    Kōtoku, 135-8550

  • Research Site

    Nagoya, 464-8681

  • Research Site

    Osaka, 541-8567

  • Research Site

    Wakayama, 641-8510

Other trials in Japan

Spain6 sites

  • Research Site

    A Coruña, 15006

  • Research Site

    Barcelona, 08025

  • Research Site

    Barcelona, 08036

  • Research Site

    Madrid, 28041

  • Research Site

    Madrid, 28046

  • Research Site

    Seville, 41009

Other trials in Spain

Italy5 sites

  • Research Site

    Catania, 95123

  • Research Site

    Naples, 80131

  • Research Site

    Orbassano, 10043

  • Research Site

    Padova, 35128

  • Research Site

    Varese, 21100

Other trials in Italy

Netherlands5 sites

  • Research Site

    Amsterdam, 1066 CX

  • Research Site

    Amsterdam, 1081 HV

  • Research Site

    Maastricht, 6229 HX

  • Research Site

    Nijmegen, 6525 GA

  • Research Site

    Rotterdam, 3015GD

Other trials in Netherlands

South Korea4 sites

  • Research Site

    Seongnam-si, 13620

  • Research Site

    Seoul, 03722

  • Research Site

    Seoul, 05505

  • Research Site

    Seoul, 06351

Other trials in South Korea

Norway3 sites

  • Research Site

    Drammen, 3004

  • Research Site

    Oslo, N-0310

  • Research Site

    Trondheim, 7030

Other trials in Norway

Denmark1 site

  • Research Site

    Odense C, 5000

Other trials in Denmark

Sweden1 site

  • Research Site

    Stockholm, 17176

Other trials in Sweden

About this study

Official title: A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy.

Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.

Read the detailed description

This is an open-label, multicentre, multi-drug, biomarker-directed Phase 2 platform study in patients with advanced non-small cell lung cancer (NSCLC) harbouring an epidermal growth factor receptor (EGFR)-sensitizing mutation whose disease has progressed on first-line monotherapy with osimertinib.Treatment options for these patients are limited. Novel treatments for these patients are urgently required.

This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.

Being tested
Osimertinib, Savolitinib, Gefitinib, Necitumumab, Durvalumab
Keywords
Non-small cell lung cancer, NSCLC, tSCLC, NEC, Phase II, Platform study, Biomarker-directed, Durvalumab, Osimertinib, Savolitinib, Selumetinib, Etoposide, Gefitinib, Necitumumab, Platinum-containing doublet, Pemetrexed, EGFR positive, Carboplatin, Alectinib, Selpercatinib
Medical subject headings
Carcinoma, Non-Small-Cell Lung

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • OsimertinibDrug

    Also called TAGRISSO

    Osimertinib given orally at 80 mg once daily

  • SavolitinibDrug

    Savolitinib will be given orally at 300 mg or 600mg once daily

  • GefitinibDrug

    Also called Iressa

    Gefitinib given orally at 250 mg once daily

  • NecitumumabDrug

    Also called Portrazza

    Necitumumab given IV at 800 mg on Day 1 and Day 8 of every 3-week cycle

  • DurvalumabDrug

    Also called IMFINZI

    Durvalumab given IV at 1500 mg on Day 1 of every cycle

  • CarboplatinDrug

    Carboplatin given IV on Day 1 of every 21-day cycle for up to 6 cycles

  • PemetrexedDrug

    Pemetrexed given IV at 500 mg/m2 body BSA on Day 1 of every cycle

  • AlectinibDrug

    Also called Alecensa

    Alectinib given orally at 600mg twice daily and for Japanese patients at 300mg twice daily.

  • SelpercatinibDrug

    Also called Loxo-292, Retevmo, Retsevmo

    Selpercatinib given orally at 160mg twice daily

  • SelumetinibDrug

    Also called Koselugo

    Selumetinib given orally at 75 mg twice daily for 4 days, followed by 3 days off treatment

  • EtoposideDrug

    Etoposide 80-100 mg/m2 given IV on day 1, 2 and 3 of every 21-day cycle for up to 4 cycles.

  • CisplatinDrug

    Cisplatin 75-80 mg/m2 given IV on days 1 of each cycle

  • Datopotamab deruxtecanDrug

    Also called DS 1062a

    Datopotamab deruxtecan given IV at 4 or 6 mg/kg on Day 1 of every 3-week cycle.

Study groups in NCT03944772
Study groupRoleWhat they receive
Module 1: Osimertinib + SavolitinibExperimentalThe patients in this group will receive osimertinib taken in combination with savolitinib
Receives: Drug: Osimertinib; Drug: Savolitinib
Module 2: Osimertinib + GefitinibExperimentalThe patients in this group will receive osimertinib taken in combination with gefitinib
Receives: Drug: Osimertinib; Drug: Gefitinib
Module 3: Osimertinib + NecitumumabExperimentalThe patients in this group will receive osimertinib taken in combination with necitumumab
Receives: Drug: Osimertinib; Drug: Necitumumab
Module 4: Carboplatin + Pemetrexed + Durvalumab)ExperimentalThe patients in this group will receive platinum-containing doublet (carboplatin + pemetrexed) taken in combination with durvalumab.
Receives: Drug: Durvalumab; Drug: Carboplatin; Drug: Pemetrexed
Observational Cohort: No study drugNo interventionPatients in this group will not receive study treatment but receive further anticancer care (Standard of Care therapy or other experimental therapies) or supportive care, as clinically indicated, in accordance with local practice. With Group C, the aim is to understand the clinical course and/or outcome for the overall clinical population after progression on first-line monotherapy with osimertinib.
Module 5: Osimertinib + AlectinibExperimentalThe patients in this group will receive osimertinib taken in combination with alectinib
Receives: Drug: Osimertinib; Drug: Alectinib
Module 6: Osimertinib + SelpercatinibExperimentalThe patients in this group will receive osimertinib taken in combination with selpercatinib
Receives: Drug: Osimertinib; Drug: Selpercatinib
Module 7: Etoposide + Durvalumab + Carboplatin or CisplatinExperimentalThe patients in this group will receive platinum-containing doublet (etoposide + carboplatin or cisplatin) taken in combination with durvalumab.
Receives: Drug: Durvalumab; Drug: Carboplatin; Drug: Etoposide; Drug: Cisplatin
Module 8: Osimertinib + Pemetrexed + Carboplatin or Cisplatin.ExperimentalThe patients in this group will receive Osimertinib plus platinum-containing doublet (pemetrexed + carboplatin or cisplatin).
Receives: Drug: Osimertinib; Drug: Carboplatin; Drug: Pemetrexed; Drug: Cisplatin
Module 9: Osimertinib + SelumetinibExperimentalThe patients in this group will receive osimertinib taken in combination with selumetinib
Receives: Drug: Osimertinib; Drug: Selumetinib
Module 10: Osimertinib + datopotamab deruxtecanExperimentalThe patients in this group will receive osimertinib taken in combination with datopotamab deruxtecan.
Receives: Drug: Osimertinib; Drug: Datopotamab deruxtecan

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective response rate (ORR)

    The percentage of patients with a confirmed investigator-assessed complete or partial response according to Response Evaluation Criteria In Solid Tumours (RECIST) 1.1. Patients will be followed up every 6 weeks (±1 week) for the first 24 weeks and every 9 weeks thereafter until RECIST 1.1 defined disease progression or cessation of study treatment (if treating beyond progression).

    Measured: Measured from first dose until confirmed response or progression. For each patient this is expected to be 3 months on average

Secondary outcomes (6)

  1. Progression-free survival (PFS)

    The time from first dose until the date of objective disease progression or death (by any cause in the absence of progression). Patients will be followed up every 6 weeks (±1 week) for the first 24 weeks and every 9 weeks thereafter until RECIST (Response Evaluation Criteria In Solid Tumours)1.1 defined disease progression or cessation of study treatment (if treating beyond progression).

    Measured: Measured from first dose until progression. For each patient this is expected to be 6 months on average

  2. Duration of response (DoR)

    The time from the date of first response until date of disease progression or death in the absence of disease progression. Patients will be followed up every 6 weeks (±1 week) for the first 24 weeks and every 9 weeks thereafter until RECIST 1.1 defined disease progression or cessation of study treatment (if treating beyond progression).

    Measured: Measured from response until progression. For each patient this is expected to be 6 months on average

  3. Overall survival (OS)

    The time from the date of the first dose of study treatment until death due to any cause.

    Measured: Measured from first dose until death or final cohort data cut-off. For each patient this is expected to be 20 months on average

  4. Plasma/serum concentrations of therapeutic agents

    Blood samples will be collected at various timepoints to evaluate the sparse pharmacokinetics of study therapeutic agents.

    Measured: Pre-dose and 1 hour post-dose blood samples on Day 1 of Cycles 1, 3 (Cycle 2 for durvalumab), 6 for all therapeutic agents and a sample at the 90-day safety follow up for durvalumab only. (One Cycle = 21 or 28 days, depending on treatment).

  5. Plasma/serum concentrations of therapeutic agents

    Blood samples will be collected at various timepoints to evaluate the serial pharmacokinetics of study therapeutic agents

    Measured: Pre-dose and serial post-dose blood samples (1 hour, 2 hours, 4 hours, 6 hours, 8 hours) on Day 15 of Cycle 1 for alectinib and selpercatinib only.

  6. Incidence of Treatment-emergent adverse events (AEs) and serious adverse events (SAEs) as characterized and graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event [CTCAE] v5

    To evaluate safety and tolerability of each study treatment

    Measured: Continuously from first dose to end of safety follow up after study treatment discontinuation (approximately up to 21 Months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 May 2019
  2. Study start25 Jun 2019
  3. Primary completion6 May 2025 (estimated)
  4. Study completion6 May 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomised
Intervention model
Parallel groups
Model description
Phase 2 platform study in patients with advanced Non-Small Lung Cancer harbouring an epidermal growth factor receptor (EGFR)-sensitizing mutation with evidence of radiological progression following first-Line osimertinib therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments. The study will be conducted in three groups (Groups A, B and C). Patient allocation to a study treatment within each group will be based on tumour molecular profile. Biomarker positive patients or patients with histologically identifiable neuroendocrine transformation to small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (NEC) will be allocated to a biomarker-matched study treatment in Group A, patients without a biomarker will be allocated to a study treatment in Group B and patients with a biomarker amenable to therapies not currently available in ORCHARD will be allocated to Group C.
Masking
None (open label)
Enrolment
247 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03944772
Sponsor's protocol ID
D6186C00001
Other IDs
2023-504624-25-00, 2018-003974-29, 2018, 2023
Acronym
ORCHARD
Status last verified
Dec 2024
First submitted
29 Apr 2019
Last updated
30 Jan 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Publications

  • Okamoto I, Cho BC, Goldberg SB, Goldman JW, de Langen AJ, Piotrowska Z, Riess JW, Yu HA, Garcia Campelo MR, Cetnar J, Kim YJ, Novello S, Shiraishi Y, Ambrose H, Smith PE, Tang KH, Lehman JM, Le X. Durvalumab plus etoposide-platinum in patients with epidermal growth factor receptor (EGFR)-mutated advanced NSCLC and neuroendocrine transformation after first-line osimertinib: ORCHARD. Lung Cancer. 2026 Aug;218:109501. doi: 10.1016/j.lungcan.2026.109501. Epub 2026 Jun 18.

    PubMed 42361644

  • Riess JW, Yu HA, Le X, de Langen AJ, Cho BC, Piotrowska Z, Hendriks LEL, Morabito A, Bonanno L, Brustugun OT, Halvorsen TO, Kim YJ, Marrone KA, Shiraishi Y, Goldman JW, Ambrose H, Smith PE, FraenkeI PG, Tang KH, Lehman JM, Goldberg SB. Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC after progression on first-line osimertinib: ORCHARD. Ann Oncol. 2026 Jun;37(6):825-836. doi: 10.1016/j.annonc.2026.02.014. Epub 2026 Mar 2.

    PubMed 41780641

  • Le X, Baik C, Cho BC, Riess JW, Piotrowska Z, Johannes de Langen A, Goldberg SB, Goldman JW, Reguart N, Shiraishi Y, Ambrose H, Fraenkel PG, Ruiz BM, Smith PE, Tang KH, Yu HA. Osimertinib Plus Savolitinib in Patients With EGFR-Mutated Advanced NSCLC With MET Alterations After First-Line Osimertinib: Clinical Outcomes, Safety, and Biomarker Analysis: A Brief Report. J Thorac Oncol. 2026 Feb;21(2):318-327. doi: 10.1016/j.jtho.2025.10.009. Epub 2025 Oct 21.

    PubMed 41130408

  • Riess JW, de Langen AJ, Ponce S, Goldberg SB, Piotrowska Z, Goldman JW, Le X, Cho BC, Yoneshima Y, Ambrose H, Cavazzina R, Tang KH, Lau J, Yu HA. ORCHARD: Osimertinib Plus Necitumumab in Patients With Epidermal Growth Factor Receptor-Mutated Advanced Non-Small Cell Lung Cancer With a Secondary Epidermal Growth Factor Receptor Alteration Whose Disease Had Progressed on First-Line Osimertinib. JCO Precis Oncol. 2025 Jun;9:e2400818. doi: 10.1200/PO-24-00818. Epub 2025 Jun 4.

    PubMed 40466026

  • Lu S, Wu L, Wang Q, Wang Z, Lv D, Ma R, Zhu B, van Tran N, Jiang L, Nan K, Laktionov K, Clarke S, Song M, Mann H, Liu Y, Shi X, Wu YL. Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL Study. J Thorac Oncol. 2025 Mar;20(3):366-382. doi: 10.1016/j.jtho.2024.10.024. Epub 2024 Nov 7.

    PubMed 39521433

  • Yu HA, Goldberg SB, Le X, Piotrowska Z, Goldman JW, De Langen AJ, Okamoto I, Cho BC, Smith P, Mensi I, Ambrose H, Kraljevic S, Maidment J, Chmielecki J, Li-Sucholeiki X, Doughton G, Patel G, Jewsbury P, Szekeres P, Riess JW. Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clin Lung Cancer. 2021 Nov;22(6):601-606. doi: 10.1016/j.cllc.2021.06.006. Epub 2021 Jun 25.

    PubMed 34389237

  • Schmid S, Fruh M, Peters S. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice? Lancet Oncol. 2020 Mar;21(3):320-322. doi: 10.1016/S1470-2045(19)30859-9. Epub 2020 Feb 3. No abstract available.

    PubMed 32027845

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Osimertinib, Savolitinib and Gefitinib in people with Non-Small Cell Lung Cancer, run by AstraZeneca at 47 sites in 9 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: under way, not looking for participants, as of the sponsor's last update on 30 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 47 sites in United States, Japan, Spain, Italy, Netherlands and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective response rate (ORR) (time frame: Measured from first dose until confirmed response or progression. For each patient this is expected to be 3 months on average). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03944772, which also lists 7 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jan 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in